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Purpose: Bacterial eye infections are commonly treated with topical antibiotics, despite limited 
evidence of effectiveness. Azithromycin 1% in DuraSite® is a new formulation of azithromycin 
in a gel polymer designed for use in acute bacterial conjunctivitis.
Methods: We conducted systematic searches of the Cochrane Database of Clinical Trials, 
PubMed and Google Scholar to find randomized controlled trials of “­azithromycin DuraSite®”. 
These searches of published literature were supplemented with searches for unpublished trials 
and trials in progress.
Results: We found six reports of randomized controlled trials investigating the role of 
 azithromycin 1% in DuraSite® for the management of acute bacterial conjunctivitis. The quality 
of these trials was judged to be moderate to high. These trials assessed effectiveness, tolerability 
and safety outcomes, but we found no trials looking at cost-effectiveness. DuraSite® is a relatively 
stable formulation and so azithromycin 1% in DuraSite® has a simpler dosing schedule than 
other available topical antibiotics. It appears to be similar to other topical antibiotics in its 
effectiveness, but minor side effects are quite common.
Conclusion: Acute bacterial conjunctivitis is a relatively mild, typically self-limiting, infection. 
Antibiotics should seldom be required. If, however, a decision to prescribe antibiotics is made, 
azithromycin 1% in DuraSite® is likely to be broadly comparable in its effectiveness to most other 
antibiotics used to treat acute bacterial conjunctivitis. Further research is needed to determine 
its cost-effectiveness.
Keywords: conjunctivitis, bacterial eye infection, azithromycin 1% in DuraSite®
Introduction
Bacterial eye infections are common, accounting for up to 1% of consultations in 
 primary care.1,2 Patients typically experience unpleasant symptoms of a “­gritty” eye, 
with blurred vision and increased lacrimation. On examination, crusted deposits can 
often be seen along the line of the eyelashes and the upper and lower conjunctivae 
appear infected, red, and irritated. Infection frequently spreads to involve both eyes.3 
Infective conjunctivitis is either bacterial or viral and, in the latter case, mainly caused 
by adenovirus. Bacterial conjunctivitis is a relatively minor self-limiting illness without 
serious sequelae in those with an intact immune system.4–6 Conjunctivitis occurring 
early in the neonatal period is the main exception to this general rule. This should be 
investigated and treated aggressively as it may indicate the presence of sight-threat-
ening trachoma.7 The main differential diagnoses of infective conjunctivitis include 
allergic conjunctivitis, chemical conjunctivitis and a foreign body. Although rare, the 
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major complication of bacterial conjunctivitis is the possible 
sight-threatening emergency of orbital cellulitis.
Patient considerations
It is difficult to distinguish bacterial from viral conjunctivitis 
on clinical grounds. Bacterial overgrowth may occur in 
the presence of viral conjunctivitis. Patients seek medical 
attention for symptom relief and this often results in the 
prescription of a topical antibiotic in the form of eye drops 
or ointment.8 Drops can be either soothing or irritating 
depending on their pH and viscosity.9 Ointments frequently 
blur vision and therefore tend to be prescribed for patient’s 
use just prior to bed time. Many of these topical antibiotics 
have frequent dosing regimens of up to every two hours.10 
Achieving good compliance with such preparations is, 
understandably, difficult.
Microbiological considerations
Bacteria are responsible for an estimated 50%–70% of 
all infective conjunctivitis. The most common bacterial 
 pathogens are Staphylococcus aureus, Haemophilus 
 influenzae, Streptococcus pnuemoniae, and Moraxella 
catarrhalis. The latter is often observed in children.11
There is ongoing debate as to whether widespread 
 prescribing of broad-spectrum antibiotics for minor illnesses, 
such as azithromycin for bacterial conjunctivitis, encourages 
the emergence of bacterial resistance. In vitro studies have, 
for example, found that azithromycin appears to be less 
active against S. pneumoniae and methicillin-susceptible 
S. aureus than erythromycin or clarithromycin. H. influenzae 
is, however, 2–8 times more susceptible to azithromycin than 
to clarithromycin or erythromycin. With increased beta-
lactam resistance of S. pneumoniae the search continues 
for effective alternatives.12,13 Also of relevance, is work by 
Ohnsman and Ritterband,14 who compared in vitro resistance 
to azithromycin and moxifloxacin in bacterial conjunctivitis 
isolates and found no bacterial resistance to moxifloxacin, but 
a moderate to very high bacterial resistance to azithromycin 
for S. epidermidis, S. pneumonia, and S. aureus.14
Management issues
The key management question is whether the prescription of an 
antibiotic is warranted. A recently updated Cochrane review4 
of five trials,15–19 which included a total of 1034 participants, 
found evidence that the application of topical antibiotics 
 overall improved early (days 2 to 5) clinical (relative risk 
[RR] = 1.24; 95% confidence interval [CI]: 1.05–1.45) and 
microbiological (RR = 1.77; 95% CI: 1.23–2.54) remission 
rates. Later (days 6 to 10) data found that these early advantages 
in clinical (RR = 1.11; 95% CI: 1.02–1.21) and microbiological 
(RR = 1.56; 95% CI: 1.17–2.09) cure rates persisted, but were 
reduced. The majority of cases in the placebo arms of these 
trials resolved spontaneously with clinical remission being 
achieved in 65% (95% CI: 59–70) by days 2–5. No serious 
outcomes were reported in either the active or placebo arms of 
the five trials included in this review. Synthesis of these trials 
found that the prescription of topical antibiotics marginally 
accelerated remission of acute bacterial conjunctivitis. None 
of the trials reported on cost-effectiveness considerations.
Everitt et al19 conducted an innovative trial assessing 
the impact of delayed prescribing of antibiotics for con-
junctivitis. Prescribing strategies did not affect the severity 
of symptoms, but the duration of moderate symptoms was 
reduced with antibiotics: ie, no antibiotics (control) mean 
of 4.8 days vs immediate antibiotics 3.3 days (RR = 0.7; 
95% CI: 0.6–0.8); control vs delayed antibiotics 3.9 days 
(RR = 0.8; 95% CI: 0.7–0.9).20
In this factorial trial, the researchers asked patients 
whether they thought they needed the antibiotics and also 
whether they would re-attend the surgery in future episodes 
of conjunctivitis. These questions were designed to assess 
the impact of medicalization on likely future health-seeking 
behavior.20 Everitt et al concluded that delayed prescription of 
antibiotics was probably the most effective treatment strategy, 
particularly in that this approach was likely to also change 
patterns of health-seeking behavior for future episodes of 
suspected infective conjunctivitis. However, this conclusion 
needs to be re-examined since chloramphenicol eye drops 
recently became available in the UK from pharmacists with-
out the need for a prescription.21
Another factor to be taken into account when prescribing 
for infective conjunctivitis is that children in nursery or school 
often infect one another and so institutions may ask parents 
to keep their children at home. The parents then may need to 
miss time from work to care for their children.21,22 Therefore, 
pressure from parents may result in more prescriptions for 
conjunctivitis so that children can return to childcare and 
parents can return to work as rapidly as possible.
The present review seeks to assess the place of azithro-
mycin 1% in DuraSite® (Insite Vision, Alameda, CA, USA), 
a new preparation for the management of acute bacterial 
conjunctivitis.
Methods
We used systematic review principles to search the Cochrane 
Central Database of Clinical Trials, PubMed and Google 
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Scholar with the keywords “­azithromycin DuraSite®” for the 
period 1990–2009 in order to identify randomized controlled 
trials. Key data were extracted from studies and the data 
were narratively synthesized, together with a wider body of 
literature on azithromycin DuraSite® to provide a broader 
context within which to consider these trials. We searched 
for unpublished material by searching online trials databases 
(http://clinicaltrials.gov/and http://www.controlled-trials.
com/).
Results
We found reports of six randomized controlled trials23–28 
enrolling a total of 2933 patients. Two of these were as yet 
unpublished in their full form.24,26 There were three reports23–25 
focusing on clinical effectiveness: two23,24 comparing 
azithromycin 1% in DuraSite® with placebo (vehicle) and a 
randomized controlled trial25 comparing azithromycin 1% in 
DuraSite® with tobramycin 0.3%, all in patients with clinically 
diagnosed conjunctivitis. The searches of the online trial data-
bases listed details of one planned and one ongoing study of 
azithromycin 1% in DuraSite® and 0.1% dexamethasone for 
blepharo-conjunctivitis.
In total, three reports26–28 included details of safety and 
tolerability: one26 comparing 1% azithromycin in DuraSite® 
with vehicle, another27 comparing it with 0.3% tobramycin 
and finally a comparison with 0.5% moxifloxacin.28
Formulation
The studies on formulations give insight into how this 
new preparation is thought to work.29,30 Azithromycin is 
 hydrophobic and is sparingly soluble in water at neutral 
pH. Aqueous preparations of azithromycin for topical 
 administration to the eye are therefore labile at room 
 temperature and can degrade. The most stable pH for 
azithromycin in solution is 6.3 and a range of 6.3 ± 0.3 has 
therefore been set for the manufacture of the solution. This 
is within the range commonly used for ophthalmic solutions. 
Azithromycin 1% in DuraSite® has been shown to be stable 
in formulation for at least 24 months at refrigerated storage 
temperatures (∼5°C). Stored at room temperature for six 
months, ocular formulation samples maintained 93%–98% 
of their azithromycin content.30
DuraSite® is a polycarbophil (polymer of polyacrylic 
acid) bio-adhesive support matrix, which facilitates topical 
delivery of azithromycin.29 It binds neutral, cationic and 
anionic small molecules and then releases these over a period 
of time in a controlled fashion. The cross-linked polymer 
chains form hydrogen bonds with glycosaminoglycans in 
mucus. Polycarbophil is therefore sometimes described as 
being muco-adhesive. This delivery mechanism ensures that 
the azithromycin is “­glued” to the eye conjunctiva, where it 
persists for longer than less “­sticky” alternatives, which offers 
the benefit of a less-frequent dosing regimen.
Also relevant is that at high shear stress, such as when 
dispensed from a bottle tip, the azithromycin 1% in DuraSite® 
flows and spreads over the ocular surface. When the shear 
stress is removed the polymer returns to a gel state, which, 
in contrast with conventional aqueous drops, limits its loss 
through reflex tearing and naso-lacrimal drainage. This 
results in a sustained level of medication on the conjunctiva, 
which makes the formulation useful for treatment of ocular 
surface infections.29
Azithromycin 1% in DuraSite®’s persistence on the eye’s 
surface means that it needs to be administered only twice 
daily for the first two days, and then only once a day for 
days 3–5 to complete the course. The full treatment course, 
comprising of a total of only seven doses, is thus potentially 
very convenient for patients. This is in contrast to drugs such 
as tobramycin which require dosing four times a day.
An azithromycin 2% in DuraSite® delivery system 
has been evaluated in rabbits and its pharmacokinetic/
pharmacodynamic profile suggests that it may have efficacy 
against common bacteria with just one dose per day for three 
days. Again, it is hoped that such a dosing regimen will, when 
made available for humans, improve concordance.30
Mode of action
Azithromycin is a macrolide antibiotic derived from 
 erythromycin. It has better stability than erythromycin in acidic 
environments. Azithromycin works by binding the 50s subunit of 
the 70s bacterial ribosome, thereby inhibiting RNA-dependent 
protein synthesis and preventing bacterial growth.31
Kinetic properties
Pharmacokinetics (ie, absorption, distribution, metabolism, 
and elimination) are predictive of the concentration and time-
course of the drug in the body, but do not necessarily correlate 
with expected antibacterial effect. The regimen of once-a-day 
dosing for five days demonstrated that peak concentrations 
of 150–200 µg/g and trough concentrations of 40 µg/g were 
sustained during a 24 hour period. These concentrations are 
higher than the minimum inhibitory concentrations (MICs) 
needed to combat eye surface infections.31 In vitro stud-
ies have confirmed that once-a-day dosing is adequate to 
provide antibiotics at a level high enough to counter typical 
conjunctival pathogens.
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There are some caveats to this advantage to consider, 
however. As azithromycin is used less frequently than other 
topical antibiotic preparations, each dose represents a greater 
percentage of the total dose and this means that missing a 
dose has greater significance. When doses are missed, the 
infection can take longer to resolve and there is the theoretical 
possibility that resistance is more likely to arise when trough 
concentrations fall below the MIC for prolonged periods.
Clinical effectiveness
Table 1 summarizes key data from trials assessing the 
 effectiveness of azithromycin 1% in DuraSite®. There are 
two studies23,24 comparing azithromycin 1% in DuraSite® 
with vehicle, both of which have used an appropriate 
randomization technique. The patients and clinicians who 
were rating the clinical and bacterial cure levels were 
blinded to the allocation of the patients. Overall, these 
studies appear to have been of moderate to good quality. 
The Abelson-controlled Phase III clinical trial27 for bacte-
rial conjunctivitis was performed with 316 randomized 
participants aged 1–96 years. A five-day regimen of 1% 
azithromycin in DuraSite® was compared with a five-day 
regimen of 0.3% tobramycin eye drops administered four 
times a day. Twenty drops of masked study medication were 
given to all participants. In the azithromycin in DuraSite® 
arm, subjects received active drug in a twice-daily load-
ing dose on days 1 and 2 and once daily on days 3–5 and 
vehicle drops were administered at other times. On day 6, 
clinical resolution rates of 1% azithromycin in DuraSite® 
were found to be equivalent to 0.3% tobramycin (79.9% vs 
78.3%; P = 0.78). Bacterial eradication was defined as the 
absence of detectable levels of new pathogens in cultures 
taken at study exit. Bacterial eradication with azithromycin 
1% in DuraSite® was reported as being as effective as with 
0.3% tobramycin (88.1% vs 94.3%; P = 0.07).
Lichtenstein and Granet28,32 have, however, been criti-
cal of this study. They argue that the addition of twice 
daily vehicle drops to the azithromycin 1% in DuraSite® 
drops constituted a possible additional therapeutic effect. 
That is, that the vehicle drops possibly diluted the infec-
tion and washed it out of the eye giving the azithromycin 
1% in DuraSite® arm of the trial an artif icially enhanced 
appearance of effectiveness. They argue that the azithro-
mycin 1% in DuraSite® arm does not represent a true once 
daily regimen due to this “­washout” effect of the vehicle 
drops. When Lichtenstein and Granet considered all 
factors related to therapy (ie, bacterial resistance, blurri-
ness, dosing compliance, and comfort) they recommend 
ophthalmic fourth-generation fluoroquinolones, such 
as moxifloxacin, as better options for the treatment of 
conjunctivitis.33
We found no studies assessing the cost-effectiveness of 
azithromycin 1% in DuraSite®.
Safety and tolerability
Three reports26–28 (Table 2) pertain to the safety and 
 tolerability of azithromycin 1% eye drops in DuraSite®. 
Heller et al conducted a large trial with 685 participants 
and found the rate of adverse events to be approximately 
12% in both the azithromycin 1% in DuraSite® arm and the 
vehicle arm in patients with bacterial conjunctivitis. Protzko 
et al27 randomized 743 patients and compared azithromycin 
1% in DuraSite® with tobramycin 0.3%. Adverse events 
observed in the azithromycin group in the Protzko trial, 
included eye irritation (1.9%), conjunctival hyperemia (1.1%) 
and worsening bacterial conjunctivitis (1.1%). Finally, the 
third study,28 which was conducted in healthy volunteers, 
tested azithromycin 1% in DuraSite® in comparison with 
 moxifloxacin 0.5%. A much higher rate of ocular adverse 
events was found in the azithromycin 1% in DuraSite® arm: 
17.3% of patients’ eyes experienced ocular adverse events 
including redness, irritation, stinging, burning, dryness, 
itching or chemosis; whereas only 1% of eyes receiving 
moxifloxacin experienced similar adverse events. This 
is a considerable difference and has implications when 
 considering whether a prescription of azithromycin 1% in 
DuraSite® should be continued for its full course by any 
patient who experiences these effects.
Patient perspectives
As nonadherence is an important consideration in bacterial 
resistance, we now consider the patients’ perspectives. This 
includes what affects their decision to consult and their 
expectations of the treatment.
There are a variety of possible reasons for patient 
nonadherence with eye drops including: poor motivation 
(stemming from lack of understanding of the function 
of the medication); inability to use eye drops properly 
(eg, difficulty aiming the drop, inability to squeeze the 
container well enough, blinking, inability to see the tip of 
the container, physical difficulties such as arthritis); and 
patients’ reluctance to admit that they have problems with 
the process.9,33
Indirect evidence on the importance of patient preferences 
comes from a study by Jampel et al34 who performed a 
 willingness-to-pay analysis on subjects taking eye drops 
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Table 1 Randomized controlled trials assessing the clinical effectiveness of azithromycin 1% in DuraSite®
Author,  
references
Number of  
patients/ 
patient age
Azithromycin Comparator Result Quality
Abelson26 N = 279  
Age 1–96
1% in DuraSite® dosed 
twice daily on days 1–2 
and once daily on  
days 3–5
Vehicle with same  
dosing schedule;  
vehicle was identically 
supplied and  
formulated except  
that it contained no 
azithromycin.
Clinical resolution with 
azithromycin in DuraSite® 
was statistically improved 
compared with that of 
vehicle P = 0.03
Prospective 
 randomized 
vehicle-controlled, 
double-masked 
study. Randomiza-
tion protocol not  
explained in 
study. Allocation 
 concealment appears 
to be adequate 
during enrolment. 
 Possible problem as 
“data monitoring 
 committee” was not 
blinded, although  
these team mem-
bers did not have 
any contact with 
study participants.
Abelson27 
 Unpublished
N = 685  
Age not available
1% in DuraSite® dosed 
twice daily for days 1–2 
and four times a day for 
days 3–5
Vehicle with same  
dosing schedule.
Clinical resolution and 
 bacterial eradication 
­significantly­better­in­ 
the azithromycin group  
than in the vehicle  
group P  0.05.
Unpublished study, 
double–masked 
and randomized, 
but­insufficient­
 information to 
 determine quality.
Abelson29 N = 316  
Age 1–83
1% in DuraSite® dosed 
twice a day with active 
drug on days 1–2 and 
once daily days 3–5,  
other doses  
were vehicle.
Tobramycin 0.3%  
four times a day
Clinical resolution was  
79.9% in azithromycin  
group and 78.3% in the 
tobramycin group. The 
 difference in clinical 
 resolution between the  
two groups was not 
­statistically­significant­ 
(P = 0.78).
Although the study 
states that it was 
randomized there 
is no explanation of 
sequence gen-
eration or alloca-
tion concealment 
during enrolment. 
Patients could not 
have been blinded 
to their treatment 
as the viscosity of 
the drops would be 
different. The results 
may also be affected 
by incomplete 
outcome data (ie, 17 
patient withdraw-
als due to adverse 
events, 16 patients 
lost to follow-up, 
withdrawn consent 
or­lack­of­efficacy).
for glaucoma. They found that patients preferred drops 
that did not produce blurring, drowsiness or inhibit sexual 
performance. If such drops were available, then patients 
would be willing to pay more for them than for drops with 
such side effects. Willingness-to-pay analysis may be useful 
when adapted for investigating the preferred characteristics 
of antibiotic eye drops in a population of subjects with 
conjunctivitis.34
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Further research
The willingness-to-pay study design discussed above could 
be used to determine whether patients would be prepared to 
pay more for the convenient dosing schedule of azithromycin 
1% in DuraSite®.
We did not find studies comparing azithromycin 1% in 
DuraSite® to chloramphenicol ointment/drops or to fusidic 
acid drops. Since these are the two antibiotics most commonly 
prescribed in the UK, a comparison of their effectiveness and 
costs would be particularly useful. This is also relevant because 
 chloramphenicol has an inconvenient dosing schedule (ie, 
every two hours), which can result in doses being missed or 
delayed. Fusidic acid drops are administered twice a day and 
so are more comparable with azithromycin 1% in DuraSite®. 
Research needs to be carried out before a recommendation 
of the place of azithromycin in the UK can be made. Studies 
comparing azithromycin 1% in DuraSite® with the topical 
treatments most commonly used in other parts of the world 
are also needed to inform local prescribing decisions. Such 
trials should focus on patient-reported outcome measures and 
should also assess cost-effectiveness considerations.
Conclusion
Based on the evidence of the Cochrane review and Everitt 
et al’s randomized controlled trial incorporating a delayed 
treatment arm, we believe there is a strong argument for not 
prescribing antibiotics for the treatment of acute bacterial 
conjunctivitis as this is, in the majority of cases, a relatively 
minor self-limiting illness. Furthermore, treatment may also 
increase the risk of development of antibiotic resistance in 
the community and also runs the risk of unnecessary medi-
calization of this problem.
If, however, a decision to prescribe antibiotics is made, 
the available evidence suggests that azithromycin 1% in 
Table 2 Randomized controlled trials assessing safety and tolerability of azithromycin 1% in DuraSite®
Author,   
references
Number of  
patients/ 
patient age
Azithromycin Comparator Result Quality
Heller27 N = 685  
Age 1–96
1% in DuraSite® twice  
daily for 2 days then  
four times a day for days  
3–5 in adults and  
children.
Vehicle with same  
dosing schedule.
12% of patients  
experienced at  
least one adverse  
event in both the  
Azasite (azithromycin  
1% in DuraSite®) and  
vehicle groups. No  
drug-related serious  
adverse events.
Unpublished study  
from Cochrane 
 register of  
trials. Double-masked 
and randomized. No 
summary statistics 
reported.
Protzko28 N = 743  
Age 1–93
1% in DuraSite® dosed  
twice a day with active  
drug on days 1 and 2 
 and once daily days  
3–5; other doses were  
vehicle.
0.3% Tobramycin  
four times a day  
for 5 days.
Both medications  
well-tolerated.  
A reported 3% of  
azithromycin group  
and 5.6% of  
tobramycin group had  
treatment-related  
adverse events.  
Rates of microbial  
eradication and  
bacterial infection  
recurrence were the  
same in both groups.
Prospective 
 randomized  
active-controlled 
 double masked 
study, but no details 
of randomization 
protocol given in 
study. The medication 
was masked. No odds 
ratios reported.
Granet28 N = 125  
34 adults and  
50 children received  
moxifloxacin­and­ 
contralateral  
azithromycin; 11  
adults and 10 children  
received­moxifloxacin­and­
contralateral placebo
1% azithromycin in  
DuraSite®
Tears Natural II®  
or­moxifloxacin­ 
0.5% in  
contralateral  
eyes.
Ocular adverse events  
were observed in 17%  
of participants  
receiving azithromycin  
1% in DuraSite® and  
1% receiving  
moxifloxacin.­ 
­Moxifloxacin­was­ 
significantly­more­ 
tolerable in  
healthy eyes.
This study was 
 supported by Alcon 
and used Alcon’s 
 preparation of 
­moxifloxacin.­No­
 summary statistics 
were reported.
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DuraSite® (Box 135) is likely to be as effective as other topical 
antibiotics. Its main advantage is a convenient once-a-day 
dosing schedule, which may aid concordance. This benefit 
may be offset however by a relatively high risk (compared 
with tobramycin and moxifloxacin) of minor side effects. 
We did not find data formally assessing cost-effectiveness 
considerations.
In summary, we suggest that the preferred course of 
action is not to prescribe antibiotics for the management of 
acute bacterial conjunctivitis, with the delayed prescription 
strategy being a proven alternative approach. In the minor-
ity of patients who may need to be given an antibiotic, this 
needs to be prescribed by the physician after considering the 
patient’s preferences regarding convenience, side effects, 
safety, effectiveness, and cost.
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Box 1 Key considerations for prescribing azithromycin 1% in DuraSite
• Licensed for use in those aged over 1 year
•  Use in pregnancy only if clearly needed, as some animal data have 
shown maternal toxicity
•  Exercise caution in breast-feeding mothers as it is not known 
whether it is excreted in breast milk
• Dosing twice a day for 2 days then once a day for 3 days
•  The most common adverse reaction reported in patients is eye 
irritation (in 1%–2% of patients).
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